Quantity of eligible patients: CDEC discussed the uncertainty in the volume of people with reasonably critical to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some people that are categorized as getting mild or average ailment could have a serious bleeding phenotype, https://beaunrrqp.blogrenanda.com/42446904/5-simple-statements-about-hemgenix-explained